<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (MDSs) are <z:hpo ids='HP_0011010'>chronic</z:hpo> and often progressive myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> associated with remarkable <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in the histomorphology and clinical course </plain></SENT>
<SENT sid="1" pm="."><plain>Various <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> are involved in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, mutations in a gene encoding a spliceosomal protein, SF3B1, were discovered in a distinct form of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with ring sideroblasts </plain></SENT>
<SENT sid="3" pm="."><plain>Whole exome sequencing of 15 patients with myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> was performed, and <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in spliceosomal genes were identified </plain></SENT>
<SENT sid="4" pm="."><plain>Sanger sequencing of 310 patients was performed to assess phenotype/genotype associations </plain></SENT>
<SENT sid="5" pm="."><plain>To determine the functional effect of spliceosomal mutations, we evaluated pre-<z:chebi fb="2" ids="33699">mRNA</z:chebi> splicing profiles by <z:chebi fb="40" ids="33697">RNA</z:chebi> deep sequencing </plain></SENT>
<SENT sid="6" pm="."><plain>We identified additional <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in spliceosomal genes, including SF3B1, U2AF1, and SRSF2 </plain></SENT>
<SENT sid="7" pm="."><plain>These mutations alter pre-<z:chebi fb="2" ids="33699">mRNA</z:chebi> splicing patterns </plain></SENT>
<SENT sid="8" pm="."><plain>SF3B1 mutations are prevalent in low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with ring sideroblasts, whereas U2AF1 and SRSF2 mutations are frequent in <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and advanced forms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>SF3B1 mutations are associated with a favorable prognosis, whereas U2AF1 and SRSF2 mutations are predictive for shorter survival </plain></SENT>
<SENT sid="10" pm="."><plain>Mutations affecting spliceosomal genes that result in defective splicing are a new leukemogenic pathway </plain></SENT>
<SENT sid="11" pm="."><plain>Spliceosomal genes are probably <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressors, and their mutations may constitute diagnostic biomarkers that could potentially serve as therapeutic targets </plain></SENT>
</text></document>